Online inquiry

IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14815MR)

This product GTTS-WQ14815MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD70 gene. The antibody can be applied in Autoimmune diseases research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001252.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 970
UniProt ID P32970
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ14815MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14874MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ14471MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RO-7105705
GTTS-WQ1088MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-838
GTTS-WQ15142MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SYNT-001
GTTS-WQ9660MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ15158MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA T1h
GTTS-WQ3783MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ9983MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA KD-247
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW